蒙特利尔认知评估量表与简易精神状态检查量表作为遗传性额颞叶痴呆患者筛查工具的比较
本研究基于荷兰和英国两项纵向遗传性额颞叶痴呆队列研究(2021-2024年)的横断面和纵向数据,纳入243名参与者(157名致病性变异携带者,86名健康对照),比较MoCA与MMSE在症状前、前驱期和症状期携带者中的筛查表现。结果显示MoCA能区分症状前携带者与对照,而MMSE不能,且MoCA的 discriminative 能力优于MMSE(AUC 0.87 vs 0.80)。作者认为MoCA因其更高的敏感性和更好的区分能力,在针对临床前FTD的临床试验中是更有价值的认知筛查工具。
要点
- MoCA可区分症状前携带者与对照,而MMSE不能。
- MoCA的区分能力优于MMSE(AUC 0.87 vs 0.80)。
- 作者认为MoCA在针对临床前FTD的临床试验中是更有价值的筛查工具。
核心结论
- MoCA因其更高的敏感性和更好的区分能力,在针对临床前FTD的临床试验中是更有价值的认知筛查工具。
- 未来研究应致力于从更多研究中心获取更大样本量。
研究设计与样本
- 使用荷兰和英国两项纵向遗传性FTD队列研究的横断面和纵向数据,收集于2021年至2024年。
- 参与者为症状前、前驱期或症状期致病性变异携带者或健康对照(无致病性变异的一级亲属)。
- 分组基于全球CDR-plus-NACC-FTLD评分。
- 参与者接受MoCA和MMSE评估,统计分析比较组间总分和子分数,并评估两种测试的预测和分类准确性。
主要发现
- 共纳入243名参与者(平均年龄49.9±13.1岁,平均教育年限14.5±3.0年,56%女性),其中157名为致病性变异携带者(MAPT、GRN、C9orf72、TARDBP和TBK1),86名为对照。
- 携带者分类为症状前(n=119)、前驱期(n=18)或症状期(n=20)。
- MoCA总分[F(3,239)=16.565,p<0.001]和MMSE总分[F(3,239)=13.529,p<0.001]在组间均存在显著差异,对照(MoCA中位数28.5,95%CI 28.0-29.0;MMSE中位数30,95%CI 30.0-30.0)优于前驱期(MoCA中位数26,95%CI 23.0-27.0;MMSE中位数29,95%CI 27.5-29.5)和症状期(MoCA中位数20.5,95%CI 17.0-24.0;MMSE中位数26,95%CI 23.5-29.0)携带者。
- MoCA可区分症状前携带者(中位数28,95%CI 27.0-29.0)与对照,但MMSE不能。
- MoCA表现出优于MMSE的区分能力(MoCA曲线下面积[AUC]=0.87,95%CI 0.81-0.94;MMSE AUC=0.80,95%CI 0.72-0.89)。
局限性
- 未来研究应致力于从更多研究中心获取更大样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: With upcoming clinical trials targeting preclinical stages of genetic frontotemporal dementia (FTD), early detection through cognitive screening is crucial. The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) have potential as screening instruments for early-stage genetic FTD. However, no comparative evaluation has been performed. We aimed to compare MMSE and MoCA performance among presymptomatic, prodromal, and symptomatic pathogenic variant carriers to analyze which screening test has superior discriminative abilities. METHODS: We used cross-sectional and longitudinal data from 2 longitudinal genetic FTD cohort studies in the Netherlands and the United Kingdom, collected between 2021 and 2024. Participants were either presymptomatic, prodromal, or symptomatic pathogenic variant carriers or healthy controls (first-degree family members without pathogenic variants for FTD). Grouping was based on the global CDR-plus-NACC-FTLD score. Participants were assessed with both MoCA and MMSE. Statistical analyses compared total and subscores between groups and evaluated predictive and classification accuracy of both tests. RESULTS: A total of 243 participants (mean age 49.9 ± 13.1 years, mean education 14.5 ± 3.0 years, 56% female), 157 of whom were pathogenic variant carriers (MAPT, GRN, C9orf72, TARDBP, and TBK1) and 86 controls, were included. Carriers were classified as presymptomatic (n = 119), prodromal (n = 18), or symptomatic (n = 20). Both MoCA [F(3,239) = 16.565, p < 0.001] and MMSE [F(3,239) = 13.529, p < 0.001] total scores differed significantly between groups, with controls (median MoCA 28.5, 95% CI 28.0-29.0; median MMSE 30, 95% CI 30.0-30.0) outperforming prodromal (median MoCA 26, 95% CI 23.0-27.0; median MMSE 29, 95% CI 27.5-29.5) and symptomatic (median MoCA 20.5, 95% CI 17.0-24.0; median MMSE 26, 95% CI 23.5-29.0) carriers. MoCA distinguished between presymptomatic carriers and controls (median MoCA 28, 95% CI 27.0-29.0), but MMSE did not. MoCA demonstrated superior discriminative ability compared with MMSE (MoCA area under the curve [AUC] = 0.87, 95% CI 0.81-0.94; MMSE AUC = 0.80, 95% CI 0.72-0.89). DISCUSSION: Its higher sensitivity and better discriminative power make MoCA a more valuable tool for cognitive screening in upcoming clinical trials targeting preclinical FTD. Future studies should aim for larger sample sizes from additional study centers.
引用
- de Boer L, Poos JM, Van Den Berg E, et al. Montreal Cognitive Assessment vs the Mini-Mental State Examination as a Screening Tool for Patients With Genetic Frontotemporal Dementia. Neurology. 2025. PMID: 39951678. doi:10.1212/WNL.0000000000213401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。